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Abstract A clinical science workshop was held at the ISHEN
meeting in London on Friday 11th September 2014 with the
aim of thrashing out how we might translate what we know
about the central role of the gut-liver-brain axis into targets
which we can use in the treatment of hepatic encephalopathy
(HE). This review summarises the integral role that inter-
organ ammonia metabolism plays in the pathogenesis of HE
with specific discussion of the roles that the small and large
intestine, liver, brain, kidney and muscle assume in ammonia
and glutamine metabolism. Most recently, the salivary and gut
microbiome have been shown to underpin the pathophysio-
logical changes which culminate in HE and patients with ad-
vanced cirrhosis present with enteric dysbiosis with small
bowel bacterial overgrowth and translocation of bacteria and
their products across a leaky gut epithelial barrier. Resident
macrophages within the liver are able to sense bacterial deg-
radation products initiating a pro-inflammatory response with-
in the hepatic parenchyma and release of cytokines such as
tumour necrosis factor alpha (TNF-α) and interleukin-8 into
the systemic circulation. The endotoxemia and systemic in-
flammatory response that are generated predispose both to the
development of infection as well as the manifestation of covert
and overt HE. Co-morbidities such as diabetes and insulin
resistance, which commonly accompany cirrhosis, may pro-
mote slow gut transit, promote bacterial overgrowth and
increase glutaminase activity and may need to be acknowl-
edged in HE risk stratification assessments and therapeutic
regimens. Therapies are discussed which target ammonia pro-
duction, utilisation or excretion at an individual organ level, or
which reduce systemic inflammation and endotoxemia which
are known to exacerbate the cerebral effects of ammonia in
HE. The ideal therapeutic strategy would be to use an agent
that can reduce hyperammonemia and reduce systemic in-
flammation or perhaps to adopt a combination of therapies
that can address both.
Keywords Hepatic Encephalopathy . Ammonia . Gut .
Liver . Brain .Muscle . Inflammation
Inter-organ ammonia and glutamine metabolism
in hepatic encephalopathy
Ammonia has for decades been considered to be central in the
pathogenesis of HE. Ammonia is neurotoxic and its accumu-
lation in the context of liver disease is multi-factorial and
involves multiple-organ systems. The liver is the predominant
ammonia-detoxifying organ in the human body. The majority
of circulating ammonia arises from intestinal breakdown of
ingested amino acids and urea. In cirrhotic patients, this pro-
cess is augmented due to increased enterocyte expression of
enterocyte phosphate-activated glutaminase (PAG) (Romero-
Gomez et al. 2004). Ammonia-rich blood reaches the liver via
the portal circulation and detoxification occurs in the liver
through either the incorporation of ammonia in the synthesis
of urea in peri-portal hepatocytes or alternatively, conversion
to glutamine by glutamine synthetase (GS) expressing peri-
venous hepatocytes (Haussinger et al. 1992). In a healthy liv-
er, these mechanisms remove almost all ammonia. The ab-
sence of hepatic GS was in a recent knock-out mouse model
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demonstrated sufficient to cause systemic hyperammonemia
(Qvartskhava et al. 2015). Indeed, in a cirrhotic liver where
both urea and glutamine synthesis are diminished by a re-
duced synthetic capacity and porto-systemic shunts allow am-
monia to bypass the liver, ammonia inevitably evades hepatic
detoxification and accumulates (Fig. 1).
In acute liver failure (ALF), rapid hepatic parenchymal
destruction causes a steep increase in ammonia as counter-
regulatory mechanisms have little time to take effect.
Increased arterial ammonia is reflected in increased intracere-
bral ammonia (Sorensen and Keiding 2007). Ammonia is
thought to cross the blood brain barrier (BBB) by means of
both passive diffusion and active transport (Nagaraja and
Brookes 1998). Within the brain, hyperammonemia disturbs
neurotransmission. High levels of ammonia cause excessive
N-methyl D-aspartate (NMDA) receptor activation, which has
been linked to adenosine triphosphate (ATP) depletion and
neuronal death (Bosoi and Rose 2009; Hermenegildo et al.
2000). In chronic hyperammonemia, adaptations lead to de-
creased cyclic guanosine monophosphate (cGMP) production
following NMDA receptor ligation, which is protective but
simultaneously slows learning abilities (Erceg et al. 2006;
Hermenegildo et al . 1998). Also a high gamma-
aminobutyric acid (GABA) tone has been demonstrated in
the cerebellum of hyperammonemic rats with neuroinhibitory
consequences (Cauli et al. 2009). Although glutamine is
a central precursor of this major inhibitory neurotrans-
mitter, the mechanism perceived to lead to an increase
in GABAergic tone per se probably relates to the
ammonia-induced production of neurosteroids by astro-
cytes, which activate GABA receptors (Ahboucha et al.
2006; Jones 2003). Both GABA and NMDA receptor
blockers have been shown to be protective in animal
models of HE (Cauli et al. 2009).
Astrocytes take part in the BBB and serve to protect the
neurons from the toxic effects of ammonia. Like the peri-
venous hepatocytes, the astrocytes express GS and can there-
by convert ammonia and glutamate into glutamine (Martinez-
Hernandez et al. 1977). The accumulation of glutamine, albeit
not directly toxic, may adversely influence cerebral function.
Firstly, glutamine functions as an osmolyte inducing astrocyte
swelling as astrocytes attempts to osmoregulate (Blei et al.
1994; Haussinger et al. 2000). This phenomenon is most pro-
nounced in ALF due to rapid ammonia accumulation, but in
chronic liver disease increased brain water is also detectable
on MRI imaging (Cordoba et al. 2001). Secondly, glutamine
in excess is transported into mitochondria and broken down to
glutamate and ammonia again; the latter causing oxidative
stress and induction of mitochondrial permeability transition
(MPT). This may create a vicious cycle of free radical forma-
tion causing further mitochondrial damage (Bai et al. 2001).
Ammonia metabolism also occurs in skeletal muscles,
which richly express GS. In patients managed with
transjugular intrahepatic portosystemic shunts (TIPSS), the
muscle is the predominant ammonia conversion site.
However, the amount of nitrogen incorporated into glutamine
exceeds that incorporated into ammonia, and any ammonia
detoxification is only temporary as kidneys and the gut rich
in glutaminase break down glutamine again (Olde Damink
et al. 2002). The only net removal of nitrogen by muscle is
performed by alanine aminotransferase, which converts pyru-
vate to alanine which is then metabolized to urea in the liver
(Felig et al. 1969). The kidneys contain both glutaminase and
GS, but are normally a net producer of ammonia with 70 % of
Inter-organ ammonia and glutamine metabolism in cirrhosis
Urea Glutamine
Fig. 1 Inter-organ ammonia and
glutamine metabolism in cirrhosis
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this being reabsorbed back into circulation and only 30 %
excreted in the urine (Olde Damink et al. 2002). When an
upper gastrointestinal bleed precipitates hyperammonemia in
patients with cirrhosis, renal production of ammonia is the
predominant source (Olde Damink et al. 2003). In some pa-
tients with cirrhosis, the kidneys can become net ammonia
excretors during hyperammonemia which can be utilized as
a therapeutic target following volume expansion with normal
saline solution in stable patients with cirrhosis (Jalan and
Kapoor 2003).
Systemic inflammation and hepatic encephalopathy
Local hepatic inflammation is a feature of both ALF and cir-
rhosis. The liver coordinates and participates in vital immuno-
logical functions given its anatomical location and vascular
supply resulting in exposure to an immense number of anti-
gens from the gut. In ALF, sudden and marked hepatic de-
struction and necrosis causes profound hepatic inflammation
(Streetz et al. 2000). In cirrhosis, bacterial overgrowth in the
gut increases the antigen load, which in combination with
ongoing liver damage is thought to trigger immune activation
in the liver. Systemic inflammation may also arise from gut-
derived antigens bypassing the liver due to portosystemic
shunting (Cirera et al. 2001). Exhaustion of immune effector
cells is a plausible result of this overwhelming effect. Indeed,
neutrophils demonstrate impaired bactericidal capacity in both
ALF and cirrhosis and this predicts the development of organ
dysfunction, infection and mortality (Taylor et al. 2013,
2014). Monocytes have also been shown to exhibit reduced
antigen presenting capabilities and TNF-α production in liver
failure (Berry et al. 2011). This renders these patients suscep-
tible to infection, which may further exacerbate the pro-
inflammatory state (Caly and Strauss 1993).
In ALF, there is a robust correlation between levels of ar-
terial ammonia and the severity of HE with levels greater than
150 μmol/L causing the most adverse phenotype of HE with
the rapid onset of cerebral edema, intracranial hypertension
and the progression to cerebral herniation in up to 25 % of
patients (Bernal et al. 2007; Clemmesen et al. 1999). Yet in
chronic liver disease, the severity and manifestation of HE is
far more variable and sensitive to the presence of precipitating
factors (Vilstrup et al. 2014). Indeed, in cirrhosis although HE
grade somewhat parallels increasing arterial ammonia concen-
tration, hyperammonemia can be detected in patients without
HE and likewise normal ammonia levels can be found in those
exhibiting grade III/IV HE (Ong et al. 2003; Shawcross et al.
2011). An increasing body of evidence points to infection,
inflammation and systemic oxidative stress being important
in modulating or even precipitating HE (Rolando et al.
2000; Shawcross et al. 2004; Takada et al. 2001). In ALF,
development of infection and systemic inflammation is
associated with the progression of HE to more advanced
stages (Rolando et al. 2000; Vaquero et al. 2003).
In cirrhosis, a strong correlation between levels of TNF-α
and HE exist with TNF-α concentration independently
predicting the severity of HE (Odeh et al. 2005). Furthermore,
resolution of inflammation improves cognitive and motor func-
tion in HE. Induced hyperammonemia in infected patients with
cirrhosis worsened neuropsychological function whilst there
was evidence of a systemic inflammatory response syndrome
(SIRS) but not following resolution of infection despite
hyperammonemia (Shawcross et al. 2004). Furthermore, in
portocaval shunt operated rats non-steroidal anti-inflammatory
treatment with ibuprofen improved cognitive impairment. This
together supports a synergistic effect of ammonia and inflam-
mation in HE (Cauli et al. 2007; Wright et al. 2007a).
Circulating cytokines such as TNF- α and interleukin-1β
induce nitric oxide (NO) and prostanoid synthesis in endothe-
lial cells eliciting secretion of pro-inflammatory cytokines by
microglia and astrocytes (Romero et al. 1996). Cytokines can
also be directly exported across the BBB (Banks et al. 1991,
1994). Brain autopsies from patients with cirrhosis who died
of HE also demonstrate microglial activation (Zemtsova et al.
2011) and brain cytokine flux measured in patients with ALF
support an intrathecal cytokine production (Wright et al.
2007b). Moreover, inflammatory hyperemia could increase
ammonia delivery to the brain (Jalan et al. 2004).
Exaggerated production of reactive oxygen species (ROS)
by neutrophils may also add to the state of systemic oxidative
stress, which arises from the unbalanced release of oxidant
and antioxidant proteins by the diseased liver (Chen et al.
1997). In patients with cirrhosis with similar ammonia levels,
those with minimal HE have higher plasma levels of systemic
oxidative stress markers than patients without (Montoliu et al.
2011). Oxidative stress is shown to increase brain water in
concert with ammonia and may thereby be involved in the
pathogenesis of HE (Bosoi et al. 2012).
Etiologically and mechanistically, ammonia and inflamma-
tion are clearly intertwined concepts in the setting of HE.
Systemically, ammonia can in itself act upon neutrophils to
increase their ROS production and lower their ability to
phagocytose bacteria (Shawcross et al. 2008). In terms of
brain inflammation, ammonia can directly or via oxidative
stress induced by MPT or lactate accumulation activate mi-
croglia (Jiang et al. 2009). Furthermore, induction of heme-
oxygenase-1 (HO-1) and inducible nitric oxide synthase
(iNOS) can be demonstrated in astrocyte cultures exposed to
a combination of ammonia and pro-inflammatory cytokines
(Chastre et al. 2010). Thus, both ammonia and inflammation
must be kept in mind when searching for efficacious treatment
strategies in HE.
Reduced production of antioxidants as the liver’s synthesis
capacity decreases combined with an increased production of
ROS from hepatocyte destruction, neutrophil dysfunction etc.
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creates a state of systemic oxidative stress which like systemic
inflammation may be an important modulating factor in HE
development (Bosoi et al. 2012).
The role of the gut as the driver of systemic
inflammation in hepatic encephalopathy
Human beings are colonized by a massive variety of microor-
ganisms collectively known as the human microbiota, which
consist of bacteria, fungi, viruses, archaea (single-celled
prokaryotes) and protozoa (Morgan et al. 2013). The compos-
ite of the genes that are harbored by these microorganisms and
the environmental milieuwithin which they reside and interact
is referred to as the human microbiome (Turnbaugh et al.
2007). The gastrointestinal tract is of most relevance to liver
pathology not only because of its intimate anatomical relation-
ship to the liver via the portal vein, but the quantum difference
in diversity and sheer number of microbial species contained
within the gut compared to other sites. The gut microbiota
consists of tens of trillions of microorganisms which outnum-
ber human cells by a factor of ten and weigh in at up to 2 kg en
masse (Baquero and Nombela 2012). About two-thirds of the
entire gut microbiome is unique to each individual, and the
genomic content of these microbes as a whole consists of over
three million genes, a staggering 150 times the amount
contained within the entire human genome (Human
Microbiome Project 2012; Qin et al. 2010). The gut microbi-
ota consists of over 1,000 species of bacteria, but only up to
170 species predominate in any given individual with
Bacteroidetes and Firmicutes being the dominant phyla
(Lozupone et al. 2012).
The density of microbiota increases significantly in the
jejunum and ileum in comparison to the gastric cavity and
duodenum. However, it is within the colon that the most
densely populated area is to be found, where there are over
1000 colony forming units/mL mainly composed of anaer-
obes such Bacteroides, Porphyromonas, Bifidobacterium,
Lactobacillus, and Clostridium. These anaerobic bacteria out-
number aerobic bacteria by a factor of 100 to 1000:1 due to the
low concentrations of oxygen within the colon, and have
evolved to thrive in this hostile ecosystem. The composition
of the gut microbiota varies within the intestinal lumen de-
pending on the level of the gut being interrogated and the
luminal diameter at that point, with certain microorganisms
more adherent to the mucosal surface whilst others predomi-
nate in the lumen itself and are more representative of the
composition measured from fecal samples.
Whilst the complex and synergistic role of gut flora and its
relationship with the human host is still being studied, ad-
vanced by the recent explosion in high throughput culture-
independent sequencing and genomic techniques, it is now
known that the gut microbiota have essential functions in
complex metabolic pathways, nutrition, homeostasis and the
development and maintenance of the innate and adaptive im-
mune systems (Guarner and Malagelada 2003). In particular,
the production of short-chain fatty acids (SCFAs) from dietary
starches which are otherwise indigestible, mainly by bacteria
from the Bacteroidetes phylum, have anti-inflammatory and
immune signaling properties as well as acting as a vital sub-
strate for energy production for intestinal mucosal cells which
helps to maintain barrier function and intestinal integrity
(Smith et al. 2013). Disturbances in these mechanisms have
direct implications in the development and propagation of a
multitude of liver-centric disease processes (Cenit et al. 2014;
Owyang and Wu 2014; Shreiner et al. 2015).
It is well established that those afflicted with cirrhosis have
a multitude of intestinal factors that lead to downstream dele-
terious local and systemic effects and play a major role in
clinically adverse outcomes including HE. This is of course
in part due to the delivery of gut-derived bacteria and their
products directly to the liver via the portal vein, with the liver
being of paramount importance in needing to generate an ef-
fective innate immune response.
Small bowel bacterial overgrowth in combination with
translocation of these bacteria and their endotoxins (such as
lipopolysaccharide, flagellin, peptidoglycan and bacterial
DNA) can cross a more permeable gut epithelial membrane
increasing exposure of the liver to immune-activating bacteri-
al degradation products. This is further exacerbated by under-
lying portal hypertension and endothelial dysfunction (Wiest
and Garcia-Tsao 2005), whilst portosystemic shunting in-
creases the delivery of these bacterial products to the systemic
circulation and so evading the reticuloendothelial system
(Cirera et al. 2001).
Endotoxins activate hepatic macrophages via toll-like re-
ceptor (TLR) signaling, stimulating the production of pro-
inflammatory cytokines such as TNF-α and interleukin-8
which in turn trigger the hepatic migration of neutrophils
and monocytes (Singh et al. 2011). This ultimately culminates
in hepatic injury and systemic inflammation, and further in-
duces innate immune dysfunction predisposing to infection
and development of decompensating complications such as
hemorrhage, sepsis and HE (Bajaj et al. 2014b).
Whilst small bowel bacterial overgrowth, increased intes-
tinal permeability, translocation of bacteria and their products
and systemic inflammation are all intimately linked and con-
tribute to HE (Fig. 2), more recently the concept and confir-
mation of enteric dysbiosis in cirrhosis has attracted interest
and scrutiny. Adverse changes in gut microbiota have been
causally linked to the pathogenesis of cirrhosis and the pro-
gression to advanced liver disease. (Nolan 2010) Quantitative
metagenomic analyses have recently been employed to dem-
onstrate that 75,245 microbial genes differ in abundance be-
tween patients with cirrhosis and healthy individuals (Qin
et al. 2014).
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Changes in bacterial composition characterised by a relative
decrease in potentially beneficial autochthonous taxa as well as
a relative overgrowth of potentially pathogenic taxa (such as
Staphylococcaeae, Enterobacteriaceae, and Enterococcaceae)
was independently associated with severity of liver disease and
the development of endotoxemia and HE, suggesting a direct
pathogenic role (Bajaj 2014; Bajaj et al. 2012a, 2014b; Chen
et al. 2011; Nava and Stappenbeck 2011). The pathophysiolog-
ical mechanisms underpinning this are complex, and it has been
suggested that the reduced production of SCFAs, anti-bacterial
peptides and changes in bile acid production resulting from
enteric dysbiosis all contribute to worsening disease severity.
Indeed, it is widely recognised that intestinal decontamination
with non-absorbable antibiotics such as rifaximin is an effective
treatment for covert and overt HE (Bass et al. 2010; Sidhu et al.
2011), directly implicating gut dysbiosis in the development of
neurocognitive dysfunction.
Salivary dysbiosis is also present and is likely to an extent
to be a reflection of those pathological changes also seen af-
fecting the more distal intestinal microbiota in cirrhosis, with
an associated systemic and salivary-specific inflammatory mi-
lieu (Bajaj et al. 2015). Salivary dysbiosis was more pro-
nounced in over a third of cirrhotic patients that went on to
require liver-related hospital admissions during the 90-day
follow-up period, suggesting a causative role particularly
when considering that saliva from patients with cirrhosis is
enriched with genes related to endotoxin synthesis proteins,
and nucleic acid and vitamin metabolism, the latter of which
are purported to modulate intestinal barrier integrity and oxi-
dative stress. This in combination with evidence of a buccal
pro-inflammatory milieu with higher salivary interleukin-1β
and interleukin-6 (IL-6) concentrations and a resultant in-
crease in secretory IgA, accompanied by a reduction in
histatins 1 and 5 and lysozyme, are in keeping with impair-
ment of local innate defenses of the oral cavity. It must be said
however that the contribution of salivary dysbiosis compared
to the distal gut in cirrhosis is likely to be minimal, mainly
because of the quantum difference in the number of bacteria
between the two sites. The gut and related enteric dysbiosis is
thus the main driver of inflammation, with this organ being the
main target when considering therapeutic options such as non-
absorbable antibiotics like rifaximin.
One drawback of studies analyzing the gut microbiome in
patients with cirrhosis is that geographical differences in its
composition and function may be vastly disparate and there-
fore the location of the study e.g. China versus the USA may
make characterization of gut dysbiosis country and environ-
ment-specific.
Therapeutic strategies targeting the gut-liver-brain
axis
Traditionally therapies have looked to reduce ammonia by
utilising the gut as a target organ, starting with neomycin in
the 1970’s and quickly followed by the non-absorbable disac-
charides such as lactulose and lacitol. These remain the main-
stay of treatment in primary and secondary care (Blei and
Cordoba 2001). Non-absorbable disaccharides reduce circu-
lating ammonia by two main mechanisms; the acidification of
the gut lumen prevents urease-producing gut bacteria from
thriving thereby reducing ammonia production. This, coupled
with inhibition of ammonia diffusion from the lumen into the
circulating blood stream, effectively reduces the overall am-
monia level. Table 1 summarises these and the other therapeu-
tic strategies that have been used to manage HE in targeting
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Fig. 2 The gut-liver-brain axis in
cirrhosis
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elements of the gut-liver-brain axis. Of note, only a handful of
these therapies are available and recognised for routine use in
the clinical setting.
Although the utility of lactulose as first line in the treatment
of acute HE has been hotly debated (Als-Nielsen et al. 2004;
Shawcross and Jalan 2004) in the absence of any large
multicentre randomized controlled trial ever being performed,
there are robust data to support its use in the secondary prophy-
laxis of recurrence of overt HE (Sharma et al. 2009) and in the
treatment of covert HE (Prasad et al. 2007). Recently, the he-
patic encephalopathy: lactulose vs polyethylene glycol (HELP)
trial recently showed statistically significant reduction in both
HE grade and resolution of symptoms when polyethylene gly-
col (PEG) solution was used instead of lactulose (Rahimi et al.
2014). The increase in renal ammonia excretion as a conse-
quence of administering 4 l of PEG solution could however
explain its non-inferiority compared to lactulose in this trial.
A Cochrane systemic review and meta-analysis favoured
antibiotics such as vancomycin, neomycin and metronidazole
over non-absorbable disaccharides however their oto-, nephro-
and neurotoxicities have precluded long term use (Als-Nielsen
et al. 2004). Rifaximin, is a broad-spectrum antibiotic which
has minimal systemic absorption and has recently taken the
place of the other non-absorbable antibiotics after a large
double-blinded randomised controlled trial of 299 patients
demonstrated an improvement in maintained remission from
HE and a reduction in hospitalisations due toHE over a 6month
period in patients with cirrhosis who were administered
rifaximin versus placebo (Bass et al. 2010). Rifaximin has also
been examined in the context of patients with covert HE and
significantly improved driving simulator performances com-
pared to the placebo group (Bajaj et al. 2011). Ammonia levels
have never convincingly been shown to drop following
rifaximin therapy and increased levels of the anti-
inflammatory cytokine interleukin-10 have been identified in
the rifaximin-treated patients which may allude to its mecha-
nism of action being an anti-inflammatory rather than
ammonia-lowering in nature. Furthermore, rifaximin has been
demonstrated to reduce systemic endotoxin levels following
8 weeks of therapy changing the function but not the composi-
tion of the gut microbiome (Bajaj et al. 2013). Interestingly, a
UK multicentre retrospective study including 170 patients pub-
lished in abstract form and presented at the workshop has re-
ported that rifaximin-α therapy given for 3 months significantly
reduced hospital re-admission rates, impacting significantly on
the resource burden and reduced overall liver disease severity
(as measured by the Child Pugh andModel for End Stage Liver
Disease scores) raising the possibility that its therapeutic effect
may extend beyond modulating gut microbiota (Patel et al.
2014). Rifaximin, unlike vancomycin, has a lower risk of in-
ducing bacterial resistance and is likely to be better tolerated
than lactulose where non-compliance with the therapy due to
the characteristic unfavourable gastrointestinal symptoms is
well reported. The combination of lactulose with rifaximin
has also been shown to be superior to lactulose alone in the
treatment of acute HE (Courson et al. 2015).
Studies have shown probiotics to be non-inferior to
lactulose in secondary prevention (Agrawal et al. 2012) and
treatment of HE (Jiang et al. 2015) by preventing bacterial
overgrowth and translocation and by decreasing the pH of
the gut. Although no proven statistical benefit over lactulose,
probiotics had a better tolerated side-effect profile (Bajaj et al.
2014a). Meta-analyses of the use of probiotics with the aim of
favorably altering enteric flora towards reducing bacterial am-
monia production have however shown conflicting results;
one indicated an improvement in covert HE and secondary
prevention of overt HE (Xu et al. 2014), however another
has shown no statistically significant benefit on clinical
Table 1 Therapeutic strategies targeting the gut-liver-brain axis
Treatment Target Effect Role in ALF Role in OHE Role in MHE
Non-absorbable Disaccharides * Enteric bacteria Reduced ammonia production and reduction of
diffusion into circulation
No Yes Yes
Polyethylene glycol* Enteric bacteria Reduced ammonia production and reduction of
diffusion into circulation
No Yes No
Rifaximin* Enteric bacteria Modulation of microbiota and anti-inflammatory No Yes Yes
Probiotics* Enteric Bacteria Modulation of microbiota and anti-inflammatory
Reduced ammonia production
No ? Yes
Branched chain amino acids* Liver/Muscle Increased ammonia metabolism No Yes Yes
L-Ornithine L-Aspartate* Liver/Muscle Increased ammonia metabolism No Yes Yes
Ornithine Phenylacetate Liver/Muscle Increased ammonia metabolism and excretion Yes Yes ?
Glyceryl Phenylbutyrate Liver Increased ammonia metabolism and excretion No Yes ?
Metformin* Liver/Muscle Decreases glutaminase activity No Yes Yes
Albumin dialysis* Humoral factors Anti-inflammatory and anti-oxidant Yes Yes No
Plasmapheresis* Humoral factors Anti-inflammatory and anti-oxidant Yes Yes No
Therapies in routine clinical use are asterisked *
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outcomes (McGee et al. 2011). There is agreement that there
has so far been no significant negative impact with probiotic
use but further wide-scale randomised controlled trials are
needed to evaluate their future use.
Having identified systemic inflammation as a co-factor in
HE, therapies which target the reduction in cytokine and am-
monia generation potentially work to reduce the development
of inflammation within the brain. It is common for patients
with cirrhosis to have coexistent zinc deficiency. Zinc is a co-
factor for both GS and acetyl transcarboxylase; therefore de-
ficiency can lead to increased circulating ammonia levels
through decreased metabolism (Marchesini et al. 1996;
Yoshida et al. 2001). Oral zinc supplementation alone had
significant improvement on the incidence and severity of HE
but clinical trials have yet to be performed (Takuma et al.
2010). Conversely, excess manganese deposition in the basal
ganglia and globus pallidum has been proposed to induce or
enhance encephalopathic symptoms in CLD (Maffeo et al.
2014; Pomier-Layrargues et al. 1995). Molecular Adsorbents
Recirculating System (MARS)may improve HE via reduction
and removal of these circulating toxins thus suggesting zinc
may have an additional role to play in HE.
In ALF, and HE associated with cirrhosis, albumin dialysis
and plasmapheresis have been shown to have statistically sig-
nificant benefit in both reduction of HE grade and resolution
of symptoms (Banares et al. 2013; Stenbog et al. 2013).
Studies have also shown increased speed of recovery when
compared with standard medical therapy (Hassanein et al.
2007). It is thought that the removal of albumin-bound toxins
has a direct effect on the neural-toxicity and inflammation via
an antioxidant effect (Quinlan et al. 2005). Plasmapheresis
works in a similar manner and review of the data has indicated
significant improvement in overt HE and survival in ALF
avoiding the need for transplantation (Stenbog et al. 2013).
In cirrhosis, the plasma amino acid profile is altered with a
reduction in branch chain amino acids (BCAAs) such as leu-
cine, isoleucine and valine (Kawaguchi et al. 2011; Marchesini
et al. 2003; Muto et al. 2005). Studies looking at supplemental
BCAA in patients with minimal and episodic HE have shown
supplemental BCAAs have utility (Plauth et al. 1993) but it has
not yet been proven to have benefit in reducing the recurrence
of overt HE. A meta-analysis of more recent trials has given
some support to the use of BCAAs in reducing all manifesta-
tions of HE with the supposition that BCAAs boost ammonia
uptake and metabolism within skeletal muscle. BCAAs have
also been proposed as an aide in the transport of ammonia
nitrogen directly out of neurons (Gluud et al. 2013, 2015).
There is no role whatsoever in protein restriction in the man-
agement of acute or chronic HE. Protein restriction propagates
muscle catabolism and discourages muscle ammonia incorpo-
ration into glutamine (Cordoba et al. 2004).
L-Ornithine-L-Aspartate (LOLA) offers substrates for the
urea cycle thus increasing glutamine synthesis and reducing
ammonia levels (Acharya et al. 2009; Rose et al. 1998). In
chronic HE, studies have shown superiority of LOLA when
compared with lactulose in preventing episodic HE (Poo et al.
2006), inducing remission of overt HE (Kircheis et al. 2002),
although has not been shown to have significant effect on min-
imal HE. More recent studies have examined the use of L-
ornithine phenylacetate in HE in the setting of both acute and
chronic liver failure which reduces cerebral edema and ammo-
nia levels (Jalan et al. 2007; Ventura-Cots et al. 2013; Ytrebo
et al. 2009). Similarly glycerol phenylbutyrate (GPB) allows
increased urinary ammonia excretion in the form of
phenylacetate glutamine. A study published in 2014 examining
the oral administration of 6 mL GPB versus placebo for
16 weeks in patients with previous episodic HE showed signif-
icant reduction in occurrence of anyHE event, as well as time to
the event following treatment initiation. The significance was
stronger if the patient was not already on rifaximin although this
may have indicated poorer baseline (Rockey et al. 2014).
Volume expansionmay have utility in reducing angiotensin
II levels and ultimately increasing renal ammonia excretion in
TIPSS and non-TIPSS patients. This study looked at only
limited infusion of isotonic saline in stable individuals with
cirrhosis and hypothesised multiple mechanisms for the ef-
fects seen including reduced renal ammoniagenesis, reduced
transport of ammonia into the renal vein and increased uptake
by target organs for example skeletal muscle, liver and brain
(Jalan and Kapoor 2003). More recently, a double-blind con-
trolled-trial looking at volume expansion with human albumin
solution (HAS) and saline administration in patients with ep-
isodic HE showed significant improvement in survival at 90-
days in patients who were administered HAS as compared
with saline although no statistical improvement was seen with
reduction rates of HE (Simon-Talero et al. 2013). Proposed
mechanisms were reduced circulatory dysfunction and re-
duced oxidative stress.
Therapeutic strategies on the horizon
There appear to be tens of different options for the treatment of
HE and yet day to day treatment still uses regularly only a few
of these. Some are more practical, some are better understood
and many of what we are discussing have only emerged in
very recent years as research into this field has ballooned. So
the question lies what else is on the horizon that may be
utilised in practical treatment?
Cystic fibrosis, metabolic syndrome and hemochromatosis
are only a few of the disease processes that can result in dia-
betes mellitus (DM) and liver disease together. The co-
existence of diabetes causes a permanent inflammatory state
via cytokine release including those already mentioned;
TNF-α and IL-6 (Basu et al. 2011), and type 2 DM has been
associated with HE in hepatitis C-related cirrhosis (Ampuero
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et al. 2012). A study has specifically looked at the effects of
metformin use in reduction of HE. The proposed mechanism
was primarily better diabetic control via decreased gluconeo-
genesis from activation of the AMP-K pathway and modula-
tion of TNF-α expression. The study showed partial inhibition
of glutaminase activity and secondly a significant reduction in
HE rates in the metformin arm versus the control arm
(Ampuero et al. 2012). The drawback to metformin however
is its relative contraindication and concern with the develop-
ment of lactic acidosis in those with advanced cirrhosis.
Fecal microbiota transplantation (FMT) to modify enteric
dysbiosis has showed significant benefit for the treatment of
resistant colitis, Clostridium difficile infection and in-
flammatory bowel disease (de Vos 2013). Therefore this
begs the question as to whether FMT could have a role
in the treatment of HE where enteric dysbiosis has been
implicated as playing an important role in its pathogen-
esis (Bajaj et al. 2012b, 2014b).
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